|Product Candidate / Program||Drug substance||Indication||Discovery||Pre-clinical||Phase I||Phase II||Phase III / Pivotal|
|eryaspase||Asparaginase||Pancreatic Cancer||EU then EU/US|
Pancreatic cancer is a particularly aggressive cancer, with a five-year survival rate of less than 10%. We believe pancreatic cancer is a suitable indication for eryaspase because it involves a large proportion of tumors that are believed to be sensitive to L-asparaginase depletion, allowing our product candidate to potentially have an impact.
We are currently conducting a Phase 2 clinical trial in Europe in pancreatic cancer patients comparing the efficacy of GRASPA in combination with chemotherapy as compared to chemotherapy alone. The primary endpoint of the study is progression-free survival.